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V1,378/V729), 42.25% for inpatient care (including medications) (mean/median:
V1,198/0V), and 9.16% for aids and remedies (mean/median: V260/V0). Around
5.72% of the insured patient population did not incur any costs in 2018, while 5.93%
of patients incurred expenses greater than V10,000. Patients in the highest spending
quintile accounted for 74.76% of all healthcare-related costs in 2018; this translates
into an average annual cost of V10,630 per person. Similarly, the most costly patients
at the 10%/5%/1% levels accounted for 59.12%/44.33%/19.43% of annual healthcare
spending (i.e. V16,768/V10,630V/V25,146/V55,122 per patient). Conclusions: The
distribution of healthcare spending is highly skewed with a minority of insured
persons causing the majority of costs. In order to improve the cost-effectiveness of
the healthcare system, it is of utmost importance to identify and characterize pa-
tients who drive healthcare costs, as well as the sectors and interventions that are
triggering high healthcare spending.
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Objectives: The AMNOG procedure has significantly reduced prices of pharmaceu-
tical products in Germany which are now even below the European average. How-
ever, the small segment of extremely high-priced drugs (annual therapy costs (ATC).
300.000V) is continuously growing, posing a considerable financial burden on the
Statutory Health Insurance. The aim of this study was to analyze this market
segment, specifically regarding the performance in the AMNOG process and to un-
derstand the underlying and consecutive market dynamics. Methods: We analyzed
data sets from the proprietary MAIS database, including all publicly available G-BA
procedures until June 2020. The ATC along with the total rebates were calculated
based on the information provided in the benefit assessment and the official price
list (Lauer Taxe). Results: Of the502completedprocedures todate, 26equivalent to22
pharmaceuticalswere themost expensive productswith netminimumannual therapy
costs of 312.129V. Themost expensive drug with 1.575.000V annual therapy costs was
betibeglogene autotemcel, a gene therapy. 77% of these pharmaceutical products were
orphan drugs with no previously existing therapy. Several of these showed positive
effects in survival endpoints. The remaining 23% were hemophilia products with
no additional benefit. Furthermore, metabolic disease (42%) and hematology
(35%) were the most frequent therapeutic areas in the high cost segment. All
high-priced products possess specific, advanced mechanisms of action including
recombinant proteins (58%), monoclonal antibodies (15%), synthetic nucleic
acids (12%), gene therapies (11%) and kinase inhibitors (4%). The total net re-
bates after negotiation varied between 14.86% and 39.05% and did not correlate
with the benefit category nor with the cost level. Conclusions: Our results
confirm the general German notion, that also in the high-price segment of
pharmaceutical drugs, there is no correlation between the negotiated rebate and
the category of the additional benefit nor with the cost level of the treatments.
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Objectives: Missed appointments (MAs) contribute to the rising costs of physio-
therapy and are a significant challenge to healthcare administration, organisational
workflow and health outcomes for patients. This study assessed prevalence and
pattern of missed physiotherapy appointments, wait time, and its impact on cost,
efficiency and patient outcome in Nigeria. Methods: A retrospective study was
conducted at the Outpatient Physiotherapy Clinic of Obafemi Awolowo University,
Ile-Ife, Nigeria. A total of 3243 physiotherapy appointments booked between 2009
and 2018 were assessed. Data were collected on socio-demographic and patient
outcomes related to Mas. MAs was defined as any appointment where a patient
did not show up at all, or attend to follow up appointment or notify staff of a
cancellation. The total revenue loss due to MAs was calculated as a product of the
total of MAs and per treatment cost. Descriptive of mean, standard deviation and
frequency and inferential statistics of t-test were used to analyse the data.
Results: MAs constituted 1701 (52.5%) of all appointments and the average wait
time for first appointment was 9.6 6 23.2 days. The proportion of MAs was higher
among females (50.2%), middle-aged adults (34-55 years) (31.7%), patients who
were not resident close to the clinic (45.3%), patients with orthopaedic conditions
(56.2%) and patients referred from orthopaedic surgeons (32.8%). There were
significant associations (p , 0.05) between MAs and age, sex, location of patient’s
residence and the source of referral. Considering the per treatment schedule cost
of 1000 naira, a 52.5% MAs rate resulted in a lower efficiency of 76.6% with an
efficiency ratio of 0.23. Conclusions: MAs for physiotherapy treatment poses a
significant challenge on costs, efficiency and patients’ outcome. Thus, an
innovative reminder system may help reduce patients’ non-attendance of phys-
iotherapy and its consequences.
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Objectives: Second-generation antipsychotics have similar effectiveness for the
treatment of schizophrenia symptoms, so drug choice is often based on differences in
rates of adverse events. Relapse is also a key driver of treatment costs. The key aim of
this study was to compare the costs due to adverse events, and how they varied
across European countries. Methods: Systematic searches were conducted to iden-
tify evidence on effectiveness and costs. A Markov model was developed to assess
the costs of ten antipsychotics: aripiprazole, brexpiprazole, cariprazine, lumateper-
one, lurasidone, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone.
Costs were obtained for seven countries: Italy, Hungary, France, Slovenia, Spain,
Sweden and the UK. The costs considered were adverse events (including diabetes,
myocardial infarction, stroke and weight gain), drug costs, relapse, treatment
discontinuation and schizophrenia management. Acute and stable adult populations
were modelled, with a life-time horizon for both. Results: For the acute population,
the lowest lifetime costs were observed for lurasidone for all seven countries. The
second lowest costs were for ziprasidone. The main drivers of cost differences were
diabetes and cardiovascular diseases, which were lowest for lurasidone, followed by
ziprasidone then lumateperone. Costs for managing weight gain were lowest for
ziprasidone and lurasidone. The stable population provided similar results. The
contribution of diabetes and cardiovascular diseases to total costs varied from less
than 40% in Slovenia and Sweden to over 70% in Hungary and Italy.
Conclusions: Lurasidone was associated with the lowest total lifetime costs in the
acute population in seven European countries compared to nine antipsychotics. This
was primarily due to the avoidance of diabetes and cardiovascular events. The
rankings of the remaining antipsychotics varied by country, emphasising the
importance of considering country-specific costs. Future research should investigate
the individual costs of relapse management, including differences in the costs and
proportions of hospitalisations.
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Objectives: Magnetic resonance imaging (MRI) with Gadobutrol (GAD), MRI with
Gadoteric Acid (GOT), and peripheral angiography (PA) methods are used in the
diagnosis of vascular disease (VD). MRI with Gadoxetic-acid (GAX), MRI with
extracellular contrast agent (ECCM), or contrast CT (CCT) are used for the diagnosis of
liver metastasis (LM). The study aimed to compare the clinical and economic out-
comes of alternative imaging methods in the diagnosis of VD and LM in Turkey.
Methods: The clinical and economic data were examined through a literature re-
view. An expert opinion survey conducted for the missing data. The data gathered
from literature and expert opinions analyzed via the decision tree model. In case of
no diagnosis with GAD for VD; it is modeled that MR contrast imaging applied with
GOT; or vice versa. PA was performed in cases in which diagnoses couldn’t be made
using both agents with MRI. The same model tree used for if the patient didn`t get
diagnosed with GAX or ECCM or CCT for LM, then MRI contrast imaging was applied
with another agent. Reimbursement guidelines of the Social Security Institutionwere
used for cost calculations. Results: The cost per patient with the diagnosis with VD
was calculated via a decision tree as 245 TL for GAD and 251 TL for GOT. 7% less PA
was needed in the GAD which avoids 29% less unnecessary treatment compared to
GOT. The diagnosis rate was 99% with GAX, 82% with ECCM, and 60% with CCT for LM.
The cost of diagnosis per patient with LM was 280 TL for CT, 229 TL for ECCM, and
280 TL for GAX. Conclusions: GAD offered more favorable cost, a higher rate of
correct diagnosis, and fewer patients who needed PA. GAX as the gold standard in
patients with LM according to clinical guidelines.
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Objectives: Discussions regarding the implementation and cost-effectiveness of lung
cancer (LC) screening using low-dose computed tomography (LDCT) are ongoing. One
way to potentially increase economic viability is by introducing combination screening.
Whether extending LC screening with screening for chronic obstructive pulmonary
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